Navigation Links
Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
Date:12/2/2008

SOUTH SAN FRANCISCO, Calif., Dec. 2 /PRNewswire/ --Cerimon Pharmaceuticals, Inc. announced today that James S. Shannon, M.D., has been appointed to the Company's Board of Directors. Dr. Shannon is a recognized pharmaceutical industry leader with more than 20 years of experience in senior development positions, most recently serving as Head of Global Development at Novartis Pharma AG in Basel, Switzerland.

"We are thrilled to welcome Dr. Shannon to our Board of Directors," stated Paul J. Sekhri, Chief Executive Officer of Cerimon Pharmaceuticals. "Dr. Shannon's expertise in identifying and advancing drug development candidates will be of great value as we seek to expand and deepen Cerimon's clinical-stage pipeline."

Dr. Shannon began his career in the pharmaceutical industry at Sterling Winthrop, where he attained the position of Senior Vice President, Clinical Development. Dr. Shannon headed Global Clinical Development during Sterling's alliance with Sanofi to develop Clopidogrel (Plavix(R)). Following this, Dr. Shannon joined Sandoz in Switzerland as Head of Drug Registration and Regulatory Affairs. He spearheaded the integration of R&D programs during Sandoz' merger with Ciba-Geigy, creating the renowned Novartis pipeline. Subsequently, Dr. Shannon held senior development positions at Novartis, ultimately being named Head of Global Development. Under Dr. Shannon's leadership, numerous drugs were developed and approved, including Diovan(R), Tekturna(R), Gleevec(R), Femara(R), Zometa(R), Reclast(R), Lucentis(R) (ex-US), Starlix(R), Visudyne(R) and Xolair(R).

Dr. Shannon received his undergraduate and postgraduate degrees from Queen's University of Belfast, where he was trained in medicine and cardiology. He also became a Member of the Royal College of Physicians (UK).

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for pain and inflammation. The Company's lead product, its topical diclofenac patch, recently reported positive Phase II results and plans to initiate the patch Phase III development program in 1Q 2009. Cerimon is financed by the premier investors, MPM, Normura Phase4 and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
2. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
5. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
6. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
11. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media Worldwide launches ... look and added functionality give the agricultural world a taste of Meister Media ... in agriculture – from precision farming via satellites and Unmanned Aerial Vehicles (UAVs) ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team ... bioLogic team explored how bacterial properties can be applied to fabric and formed into ... which move in response to humidity change. The team harvested Natto cells and applied ...
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
Breaking Biology Technology:
(Date:3/11/2016)... Germany , March 11, 2016 http://www.apimages.com ... - Cross reference: Picture is available at AP Images ( http://www.apimages.com ... from DERMALOG will be used to produce the new refugee identity ... other biometric innovations, at CeBIT in Hanover ... scanner from DERMALOG will be used to produce the new refugee ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
Breaking Biology News(10 mins):